medigraphic.com
ISSN 0035-0052 (Print)

1999, Number 1

<< Back Next >>

Rev Mex Pediatr 1999; 66 (1)

Administración de surfactante exógeno en el tratamiento del síndrome de dificultad respiratoria neonatal, en su modalidad de terapia de rescate

López TNL, Rodríguez ZJJ, Zavala MA, Mendoza DS, Torres PC

Language: Spanish
References: 15
Page: 5-8
PDF size: 121.13 Kb.


ABSTRACT

Objective. To study the effect of two rescue dose of Exsurf in neonates with respiratory distress syndrome.
Methods. A clinical control trial was performed. Participating fifty preterm newborns with Hyaline Membrane Disease. This study has two groups with 25 patients each one. Group I received two dosage of exogenous surfactant by endotracheal pathway. Group II received conventional therapy. In both groups were compared oxigenation index, middle aerea pressure, alveolo-arterial gradient and number of days with assisted mechanic ventilation.
Results. All patients of Group I and 52% of Group II showed a better level of oxigenation. Group I showed a significative reduction of the middle aerea pressure, and Group II did not show none. Less ventilation assisted days were necessary for the Group I patients (6 vs 9 days). Both groups did not have statistical significance in relation to alveolo-arterial gradient.
Conclusion. The exogenous surfactant in a life saving modality was effective in the treatment of Respiratory Distress Syndrome in patients with Membrane Hialine Disease.


REFERENCES

  1. García SJ. Síndrome de Dificultad Respiratoria. En: Gómez GM: Temas selectos sobre el recién nacido prematuro. DEMSA 1996; 217-225

  2. Ellen A, Gregory A. Biophysical aspects of surfactant system in relation to neonatal lung function. Bio Neonate 1996; 6: 165-212

  3. Flores N, López P. Ensayo clínico con surfactante para el tratamiento del síndrome de dificultad respiratoria. Perinatol Reprod Hum 1995; 9: 149-155

  4. Goldman SL. Pulmonary mechanics in premature infants one month after treatment with synthetic surfactant. J Ped 1992; 90: 25-28

  5. Tratamiento de restitución con surfactante. Clín Perinatol 1993; 4: 683-695.

  6. Martin R, Fanaroff A, Skalina M. El síndrome de dificultad respiratoria y su tratamiento. En: Fanaroff A, Martin R. Enfermedades del feto y del recién nacido. Buenos Aires: Panamericana, 1985; 524-544

  7. Stark A, Franz I. Síndrome de sufrimiento respiratorio. Clin Pediatric Norteam 1986; 2: 551-563

  8. Jobe A. Surfactant and developing lung. En: Thibeauly D, Gregory D. Neonatal Pulmonary Care. New York: Appleton-Century-Crofts, 1994; 75-79

  9. Shapiro D, Nother R, Morin F. Double blind randomized trial of a calflung surfactant extract admministered at birth to very premature infants for prevention of respiratory distress syndrome. Pediatrics 1985; 65: 593-599

  10. Martin GI, Sindel BD. Asistencia del neonato de muy bajo peso: Uso de la sustancia tensoactiva. Clin Perinatol 1992; 2: 455-462

  11. Lerdo de Tejada A, López GR, Correa C. Relación lecitina-esfingomielina, fósforo de lecitina y fosfatidilglicerol en líquido amniótico. Correlación con el síndrome de insuficiencia respiratoria idiopática. Ginecol Obstet Mex 1981; 48: 365-372.

  12. Fujiwara T, Chid S, Watobe Y, Maeta T, Abe T. Artificial surfactant therapy in hyaline membrane disease. Lancet 1980; 2: 55-58

  13. Lietchy EA, Donovan E, Purohit D. Reduction of neonatal mortality after multiple dose of bovine surfactant in low weight neonates with respiratory distress syndrome. Pediatrics 1991; 88: 10-18

  14. Canadian Exosurf Pediatric Study Group. Effect of two rescue dose of Exosurf Pediatric in 342, 750-1249 grams infants. Pediatr Res 1990; 27: 200

  15. Lozano GCH, Piña CNV, Beyer OJ, Gutiérrez MA, Martínez HB, Flores TME. Uso terapéutico del surfactante pulmonar en la enfermedad de membrana hialina. Bol Med Hosp Infant Mex 1993; 50: 481-91




2020     |     www.medigraphic.com